Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Myeloid Leukaemia

Allogeneic bone marrow transplantation from partially mismatched related donors as therapy for primary induction failure acute myeloid leukemia

Abstract

The outcome of acute myeloid leukemia patients with primary refractoriness to conventional chemotherapy is extremely poor. Allogeneic bone marrow transplants with matched sibling or matched unrelated donors provide 10–20% disease-free survival in this setting. We analyzed our transplant experience using readily available partially mismatched related donor (PMRD) in patients with primary induction failure (PIF) AML. Between March 1994 and December 1998, 13 patients with PIF AML were transplanted from 0–3 HLA antigen mismatched donors. All 12 evaluable patients engrafted at a median of day +16. Ten (77%) patients survived at least 100 days after transplant. Acute GVHD (grade II) was observed in one of 12 patients. Chronic GVHD was seen in one of 10 patients surviving beyond day 100. The major cause of failure was relapse of disease in six occurring 3–12 months after PMRD BMT. Three patients are alive without disease 14, 36 and 45 months post BMT with Karnofsky scores of 100%. The actuarial 3-year probabilities of relapse and disease-free survival were 0.54 and 0.19, respectively. We concluded that a PMRD graft is a viable option, comparable to the use of matched related or unrelated donors, in patients with PIF AML in whom time is of the essence. Bone Marrow Transplantation (2000) 27, 507–510.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Wiernik PH, Banks PLC, Case DC Jr et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia Blood 1992 79: 313–319

    CAS  PubMed  Google Scholar 

  2. Mitus AJ, Miller KB, Schenkein DP et al. Improved survival for patients with acute myelogenous leukemia J Clin Oncol 1995 13: 560–569

    Article  CAS  PubMed  Google Scholar 

  3. Montillo M, Mirto S, Petti MC et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia Am J Hematol 1998 58: 105–109

    Article  CAS  PubMed  Google Scholar 

  4. Biggs JC, Horowitz MM, Gale RP et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy Blood 1992 80: 1090–1093

    CAS  PubMed  Google Scholar 

  5. Appelbaum FR . Allogeneic hematopoietic stem cell transplantation for acute leukemia Semin Oncol 1997 24: 114–123

    CAS  PubMed  Google Scholar 

  6. Henslee-Downey J, Abhyankar S, Parrish R et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant Blood 1997 10: 3864–3872

    Google Scholar 

  7. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 1974 18: 295–304

    Article  CAS  PubMed  Google Scholar 

  8. Kaplan EL, Meier P . Nonparametric estimation from incomplete observation J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  9. Greinix HT, Reiter E, Schulenburg A et al. Matched unrelated donor marrow transplantation in patients with advanced acute leukemia Bone Marrow Transplant 1998 22: (Suppl. 4) S53–56

    Article  PubMed  Google Scholar 

  10. Mehta J, Powles R, Horton C et al. Bone marrow transplantation for primary refractory acute leukaemia Bone Marrow Transplant 1994 14: 415–418

    CAS  PubMed  Google Scholar 

  11. Forman SJ, Schmidt GM, Nademanee AP et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia J Clin Oncol 1991 9: 1570–1574

    Article  CAS  PubMed  Google Scholar 

  12. Godder KT, Hazlett LJ, Abhyankar SH et al. Partially mismatched related donors allow for early allogeneic transplant intervention and improved disease-free survival in young patients with poor prognosis acute leukemia J Clin Oncol 2000 18: 1856–1866

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chiang, K., Van Rhee, F., Godder, K. et al. Allogeneic bone marrow transplantation from partially mismatched related donors as therapy for primary induction failure acute myeloid leukemia. Bone Marrow Transplant 27, 507–510 (2001). https://doi.org/10.1038/sj.bmt.1702800

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702800

Keywords

This article is cited by

Search

Quick links